A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Status:
Completed
Trial end date:
2021-06-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the frequency of bleeding episodes in patients
receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are
assigned to continue with their regular medication. In addition, the study will assess
safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).